Maxvax

Chengdu Maxvax raises over **RMB 400 million** in Series D funding from **IDG Capital, Shenzhen Capital Group, and Ruipu Pharma** to advance its **shingles and RSV vaccine programs**. The biotech firm leverages recombinant protein technology for both human and veterinary applications, reflecting strong investor confidence in its pipeline.

Oct 2025Insight, China's Pharmaceutical IndustryNews article

Maxvax Biotech receives NMPA acceptance for its recombinant herpes zoster vaccine, developed using CHO cells and its proprietary MA105 adjuvant system. The vaccine is the first in China to hold independent intellectual property rights for a composite adjuvant platform. The company’s product is classified as a Category 1.3 drug under regulatory standards.

Oct 2025Insight, China's Pharmaceutical IndustryNews article

Maxvax and Luzhu are securing funding to advance their recombinant herpes zoster (shingles) vaccine candidates, aiming to compete with GSK’s Shingrix. Both firms are also developing new adjuvant products to enhance vaccine efficacy. The investments will accelerate clinical trials and manufacturing readiness for their vaccine programs.

Jul 2022BioSpaceNews article

MAXVAX Biotechnology and Beijing Luzhu Biotechnology each secure funding to advance recombinant herpes zoster vaccine candidates featuring novel adjuvants. The combined $104 million aims to support development of alternatives to GSK’s Shingrix vaccine. China’s biotech sector sees broader financing activity across diverse therapies and modalities.

Jul 2022InsightsNews article